The new Abbott test uses fluorescence in situ hybridization technology (FISH) and is designed to detect rearrangements of the 2p23 chromosome of the ALK gene.
The ABT-PFE collaboration for a Crizotinib companion diagnostic was announced in 2009 (#msg-40949294).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”